93 related articles for article (PubMed ID: 33143297)
1. Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer.
Piquemal D; Noguier F; Pierrat F; Bruno R; Cros J
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33143297
[TBL] [Abstract][Full Text] [Related]
2. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma.
Piquemal D; Bruno R; Bournet B; Ghiringhelli F; Noguier F; Canivet C; Bertaut A; Pierrat F; Evesque L; Gamez A; Cros J; Rederstorff E; Petit E; Adnet J; Saint A; Drouillard A; Kempf E; Soularue E; Vincent J; Baumgaertner I; Hennequin A; Tournigand C; Lopez Trabada Ataz D; Bengrine L; Lepage C; Manfredi S; Afchain P; Trouilloud I; Gagnaire A; LoConte NK; Bachet JB
J Gastrointest Oncol; 2023 Apr; 14(2):997-1007. PubMed ID: 37201091
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Abdelghani MB; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf D; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
Ann Oncol; 2024 Jun; ():. PubMed ID: 38906254
[TBL] [Abstract][Full Text] [Related]
4. Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer.
Suzuki R; Takagi T; Hikichi T; Konno N; Sugimoto M; Watanabe KO; Nakamura J; Waragai Y; Kikuchi H; Takasumi M; Watanabe H; Ohira H
Oncol Lett; 2016 May; 11(5):3441-3445. PubMed ID: 27123132
[TBL] [Abstract][Full Text] [Related]
5. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials.
Ormanns S; Haas M; Baechmann S; Altendorf-Hofmann A; Remold A; Quietzsch D; Clemens MR; Bentz M; Geissler M; Lambertz H; Kruger S; Kirchner T; Heinemann V; Boeck S
Br J Cancer; 2016 Dec; 115(12):1520-1529. PubMed ID: 27802454
[TBL] [Abstract][Full Text] [Related]
6. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
7. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
8. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
9. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
[TBL] [Abstract][Full Text] [Related]
10. Network Meta-Analysis of Efficacy and Safety of Chemotherapy and Target Therapy in the First-Line Setting of Advanced Pancreatic Cancer.
Lin KI; Yang JL; Lin YC; Chou CY; Chen JH; Hung CC
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31703359
[TBL] [Abstract][Full Text] [Related]
11. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer.
Nicolle R; Gayet O; Bigonnet M; Roques J; Chanez B; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Rebours V; Giovannini M; Grandval P; Dahan L; Moutardier V; Mitry E; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Transl Oncol; 2022 Feb; 16():101315. PubMed ID: 34906890
[TBL] [Abstract][Full Text] [Related]
12. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.
Frere C; Bournet B; Gourgou S; Fraisse J; Canivet C; Connors JM; Buscail L; Farge D;
Gastroenterology; 2020 Apr; 158(5):1346-1358.e4. PubMed ID: 31843588
[TBL] [Abstract][Full Text] [Related]
14. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data.
Giovinazzo F; Soggiu F; Jang JY; Versteijne E; van Tienhoven G; van Eijck CH; Han Y; Choi SH; Kang CM; Zalupski M; Ahmad H; Yentz S; Helton S; Rose JB; Takishita C; Nagakawa Y; Abu Hilal M
Front Oncol; 2020; 10():1112. PubMed ID: 32850319
[No Abstract] [Full Text] [Related]
16. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.
Veenstra VL; Damhofer H; Waasdorp C; van Rijssen LB; van de Vijver MJ; Dijk F; Wilmink HW; Besselink MG; Busch OR; Chang DK; Bailey PJ; Biankin AV; Kocher HM; Medema JP; Li JS; Jiang R; Pierce DW; van Laarhoven HWM; Bijlsma MF
Oncogenesis; 2018 Nov; 7(11):87. PubMed ID: 30442938
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a 12-gene expression signature to predict colon cancer prognosis.
Sun D; Chen J; Liu L; Zhao G; Dong P; Wu B; Wang J; Dong L
PeerJ; 2018; 6():e4942. PubMed ID: 29915691
[TBL] [Abstract][Full Text] [Related]
18. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival.
Amantini C; Morelli MB; Nabissi M; Piva F; Marinelli O; Maggi F; Bianchi F; Bittoni A; Berardi R; Giampieri R; Santoni G
Front Oncol; 2019; 9():874. PubMed ID: 31552188
[TBL] [Abstract][Full Text] [Related]
19. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant nab-paclitaxel plus gemcitabine
Yin ZZ; Zhao ZM; Tang WB; Jiang N; Zhang KD; Song YY; Wang Y; Li CG; Gao YX; Liu R
World J Clin Cases; 2020 Jul; 8(13):2778-2786. PubMed ID: 32742988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
